Quest Diagnostics Incorporated
DGXNYSEHealthcare● Active
$198.23
$-2.06(-1.03%)
Market Cap$21.9B
P/E Ratio—
52W High$213.5
52W Low$164.65
Quest Diagnostics Incorporated (DGX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DGX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 21, 2026EPS Actual
$2.50
Est. $2.37 · +5.5%
Revenue
$2.90B
Est. $2.83B · +2.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 21, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
DGX reports quarterly as a NYSE-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 28, 2026 | $2.81 | — | — | — | $2.98B | — |
| ▲ Q2 FY2026 | Apr 21, 2026 | $2.37 | $2.50 | +5.5% | $2.90B | $2.83B | +2.4% |
| ▲ Q1 FY2026 | Feb 10, 2026 | $2.36 | $2.42 | +2.5% | $2.81B | $2.75B | +1.9% |
| ▲ Q4 FY2025 | Oct 21, 2025 | $2.50 | $2.60 | +4.0% | $2.82B | $2.74B | +2.9% |
| ▲ Q3 FY2025 | Jul 22, 2025 | $2.57 | $2.62 | +1.9% | $2.76B | $2.73B | +1.3% |
| ▲ Q2 FY2025 | Apr 22, 2025 | $2.15 | $2.21 | +2.8% | $2.65B | $2.63B | +0.8% |
| ▲ Q1 FY2025 | Jan 30, 2025 | $2.19 | $2.23 | +1.8% | $2.62B | $2.58B | +1.6% |
| ▲ Q4 FY2024 | Oct 22, 2024 | $2.26 | $2.30 | +1.8% | $2.49B | $2.43B | +2.3% |
Q3 FY2026
Jul 28, 2026
EPS Actual
—
EPS Est.
$2.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 21, 2026Beat
EPS Actual
$2.50
EPS Est.
$2.37
EPS Surpr.
+5.5%
Revenue
$2.90B
Q1 FY2026
Feb 10, 2026Beat
EPS Actual
$2.42
EPS Est.
$2.36
EPS Surpr.
+2.5%
Revenue
$2.81B
Q4 FY2025
Oct 21, 2025Beat
EPS Actual
$2.60
EPS Est.
$2.50
EPS Surpr.
+4.0%
Revenue
$2.82B
Q3 FY2025
Jul 22, 2025Beat
EPS Actual
$2.62
EPS Est.
$2.57
EPS Surpr.
+1.9%
Revenue
$2.76B
Q2 FY2025
Apr 22, 2025Beat
EPS Actual
$2.21
EPS Est.
$2.15
EPS Surpr.
+2.8%
Revenue
$2.65B
Q1 FY2025
Jan 30, 2025Beat
EPS Actual
$2.23
EPS Est.
$2.19
EPS Surpr.
+1.8%
Revenue
$2.62B
Q4 FY2024
Oct 22, 2024Beat
EPS Actual
$2.30
EPS Est.
$2.26
EPS Surpr.
+1.8%
Revenue
$2.49B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $2.99 | $3.04 | $3.11 | 5 |
| Q3 FY2028 | $3.20 | $3.26 | $3.33 | 10 |
| Q2 FY2028 | $3.20 | $3.26 | $3.33 | 7 |
| Q1 FY2028 | $2.93 | $2.99 | $3.05 | 5 |
| Q4 FY2027 | $2.79 | $2.84 | $2.90 | 4 |
| Q3 FY2027 | $2.96 | $3.02 | $3.08 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $3.2B | $3.2B | $3.3B | 4 |
| Q3 FY2028 | $3.2B | $3.2B | $3.3B | 4 |
| Q2 FY2028 | $3.2B | $3.2B | $3.3B | 4 |
| Q1 FY2028 | $3.1B | $3.1B | $3.2B | 4 |
| Q4 FY2027 | $3.1B | $3.1B | $3.2B | 5 |
| Q3 FY2027 | $3.1B | $3.1B | $3.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 21, 2026 | +5.5% | $196.31 | $205.04 | +4.45% |
| ▲ Q1 FY2026 | Feb 10, 2026 | +2.5% | $191.25 | $205.35 | +7.37% |
| ▲ Q4 FY2025 | Oct 21, 2025 | +4.0% | $190.41 | $184.64 | -3.03% |
| ▲ Q3 FY2025 | Jul 22, 2025 | +1.9% | $166.45 | $178.24 | +7.08% |
| ▲ Q2 FY2025 | Apr 22, 2025 | +2.8% | $161.86 | $172.84 | +6.78% |
| ▲ Q1 FY2025 | Jan 30, 2025 | +1.8% | $155.44 | $164.17 | +5.62% |
| ▲ Q4 FY2024 | Oct 22, 2024 | +1.8% | $147.37 | $157.47 | +6.85% |
| ▲ Q3 FY2024 | Jul 23, 2024 | +0.4% | $147.35 | $140.96 | -4.34% |
Q2 FY2026+4.45%
Report Date
Apr 21, 2026
EPS Beat/Miss
+5.5%
Price Before
$196.31
Price After
$205.04
Q1 FY2026+7.37%
Report Date
Feb 10, 2026
EPS Beat/Miss
+2.5%
Price Before
$191.25
Price After
$205.35
Q4 FY2025-3.03%
Report Date
Oct 21, 2025
EPS Beat/Miss
+4.0%
Price Before
$190.41
Price After
$184.64
Q3 FY2025+7.08%
Report Date
Jul 22, 2025
EPS Beat/Miss
+1.9%
Price Before
$166.45
Price After
$178.24
Q2 FY2025+6.78%
Report Date
Apr 22, 2025
EPS Beat/Miss
+2.8%
Price Before
$161.86
Price After
$172.84
Q1 FY2025+5.62%
Report Date
Jan 30, 2025
EPS Beat/Miss
+1.8%
Price Before
$155.44
Price After
$164.17
Q4 FY2024+6.85%
Report Date
Oct 22, 2024
EPS Beat/Miss
+1.8%
Price Before
$147.37
Price After
$157.47
Q3 FY2024-4.34%
Report Date
Jul 23, 2024
EPS Beat/Miss
+0.4%
Price Before
$147.35
Price After
$140.96
Avg Beat Reaction+3.85%
Beat Rate8 / 8 quarters
Largest Move+7.37% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DGX ends December
Quest Diagnostics Incorporated (DGX) most recently reported earnings on April 21, 2026 for Q2 FY2026, posting EPS of $2.50 — beating the analyst consensus of $2.37 by +5.5%. DGX has beaten EPS estimates for 11 consecutive quarters. The next DGX earnings date is expected around September 1, 2026.
Each quarter, investors track DGX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DGX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DGX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DGX earnings · 5 questionsQuest Diagnostics Incorporated's next earnings report is expected around September 1, 2026. DGX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DGX historically reports after market close (AMC).
DGX earnings datewhen is DGX earningsDGX next earnings datewhen does DGX report earningsDGX earnings calendar
▸ Source: FMP · Quest Diagnostics Incorporated SEC filings · US GAAP · Quest Diagnostics Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026